ATE412006T1 - Anti-retrovirale immunogene, ihre darstellung und verwendung - Google Patents

Anti-retrovirale immunogene, ihre darstellung und verwendung

Info

Publication number
ATE412006T1
ATE412006T1 AT98964219T AT98964219T ATE412006T1 AT E412006 T1 ATE412006 T1 AT E412006T1 AT 98964219 T AT98964219 T AT 98964219T AT 98964219 T AT98964219 T AT 98964219T AT E412006 T1 ATE412006 T1 AT E412006T1
Authority
AT
Austria
Prior art keywords
immunogenes
retroviral
presentation
retroviral immunogenes
Prior art date
Application number
AT98964219T
Other languages
English (en)
Inventor
Jean-Francois Zagury
Jay Rappaport
Miguel Carcagno
Original Assignee
Neovacs
Biovacs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs, Biovacs Inc filed Critical Neovacs
Application granted granted Critical
Publication of ATE412006T1 publication Critical patent/ATE412006T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/82—Proteins from microorganisms
    • Y10S530/826—Viruses
AT98964219T 1997-12-26 1998-12-22 Anti-retrovirale immunogene, ihre darstellung und verwendung ATE412006T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716589A FR2773156B1 (fr) 1997-12-26 1997-12-26 Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida

Publications (1)

Publication Number Publication Date
ATE412006T1 true ATE412006T1 (de) 2008-11-15

Family

ID=9515202

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98959984T ATE330970T1 (de) 1997-12-26 1998-12-14 Neue anti-hiv immunogene (toxoide), herstellungsverfahren und verwendungen zur behandlung und vorbeugung von aids
AT98964219T ATE412006T1 (de) 1997-12-26 1998-12-22 Anti-retrovirale immunogene, ihre darstellung und verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98959984T ATE330970T1 (de) 1997-12-26 1998-12-14 Neue anti-hiv immunogene (toxoide), herstellungsverfahren und verwendungen zur behandlung und vorbeugung von aids

Country Status (16)

Country Link
US (2) US6420141B1 (de)
EP (3) EP1042363B1 (de)
JP (2) JP2001527029A (de)
AR (1) AR014946A1 (de)
AT (2) ATE330970T1 (de)
AU (2) AU1568499A (de)
BR (1) BR9814473A (de)
CA (1) CA2316811A1 (de)
CY (1) CY1106152T1 (de)
DE (2) DE69835031T2 (de)
DK (1) DK1042363T3 (de)
ES (1) ES2267199T3 (de)
FR (1) FR2773156B1 (de)
MX (1) MXPA00006263A (de)
PT (1) PT1042363E (de)
WO (2) WO1999033872A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
FR2781158B1 (fr) * 1998-07-15 2002-12-13 Vacs Internat Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
FR2792639B1 (fr) 1999-04-26 2003-06-06 Neovacs Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
MXPA02007413A (es) * 2000-01-31 2004-07-30 Smithkline Beecham Biolog Vacuna para la inmunizacion profilactica o terapeutica contra el vih.
WO2006033665A1 (en) * 2004-03-16 2006-03-30 Inist Inc. Tat-based vaccine compositions and methods of making and using same
US20080044435A1 (en) * 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
FR2828404B1 (fr) * 2001-08-10 2005-07-15 Neovacs Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal
CA2469487A1 (en) * 2001-12-11 2003-07-03 Aventis Pasteur Mutated hiv tat
US20050222388A1 (en) * 2002-05-16 2005-10-06 Paul Howley Fusion protein of hiv regulatory/accessory proteins
US20040115830A1 (en) * 2002-09-25 2004-06-17 Igor Touzov Components for nano-scale Reactor
FR2862306B1 (fr) 2003-11-17 2008-05-30 Aventis Pasteur Composition vaccinale
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
US8168165B2 (en) * 2008-12-23 2012-05-01 Abbott Laboratories Alkylated interleukin-18 compositions
BRPI1009215B1 (pt) 2009-03-23 2019-10-29 Nanirx Inc composição farmacêutica compreendendo uma sequência de aminoácidos modificada da proteína trans-ativadora de transcrição (tat) do vírus da imunodeficiência humana (hiv) e uso de um polipeptídeo derivado de tat para tratar câncer
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
RU2695653C2 (ru) 2013-10-04 2019-07-25 Пин Фарма, Инк. Иммуностимулирующие полипептидные производные тат вич для применения в лечении рака
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN106794241A (zh) * 2014-08-18 2017-05-31 圣诺菲·帕斯图尔公司 烷基化流感疫苗
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
FR3057438B1 (fr) 2016-10-14 2020-10-02 Univ Limoges Procede d'elicitation d'une plante au moyen d'extraits de champignons macroscopiques comestibles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
WO1986006414A1 (en) * 1985-04-29 1986-11-06 Genetic Systems Corporation Synthetic antigens for the detection of aids-related disease
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
WO1991018454A1 (en) * 1990-05-18 1991-11-28 Centre National De La Recherche Scientifique Compositions capable of blocking cytotoxicity of viral regulatory proteins and neurotoxic symptoms associated with retroviral infection
WO1994015634A1 (en) * 1992-12-30 1994-07-21 Matthias Rath Tat and rev oligopeptides in hiv treatment
EP0767678A1 (de) 1994-05-23 1997-04-16 Gideon Goldstein Kompositionen zur transaktivierung von proteinen als humanen immunschwächevirus
PL322143A1 (en) * 1995-03-08 1998-01-05 Neovacs Non-topxic immunogenes originating frommretroviral regulator protein, antibodies as such, method of preparing them and pharmaceutic compositions containing them
US6200575B1 (en) * 1996-03-07 2001-03-13 Neovacs Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
FR2773156B1 (fr) 1997-12-26 2000-03-31 Biovacs Inc Nouveaux immunogenes anti-retroviraux (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida

Also Published As

Publication number Publication date
JP2006257102A (ja) 2006-09-28
DE69835031T2 (de) 2007-01-18
EP1975173A1 (de) 2008-10-01
CA2316811A1 (en) 1999-07-08
US6420141B1 (en) 2002-07-16
FR2773156A1 (fr) 1999-07-02
AU1939799A (en) 1999-07-19
JP2001527029A (ja) 2001-12-25
EP1041888A4 (de) 2000-10-18
ATE330970T1 (de) 2006-07-15
DE69835031D1 (de) 2006-08-03
EP1041888A1 (de) 2000-10-11
DK1042363T3 (da) 2006-10-30
US7022326B1 (en) 2006-04-04
FR2773156B1 (fr) 2000-03-31
PT1042363E (pt) 2006-11-30
WO1999033872A1 (fr) 1999-07-08
AR014946A1 (es) 2001-04-11
WO1999033346A1 (en) 1999-07-08
CY1106152T1 (el) 2011-06-08
AU1568499A (en) 1999-07-19
BR9814473A (pt) 2001-10-23
ES2267199T3 (es) 2007-03-01
EP1042363A1 (de) 2000-10-11
DE69840152D1 (de) 2008-12-04
MXPA00006263A (es) 2003-07-14
EP1041888B1 (de) 2008-10-22
EP1042363B1 (de) 2006-06-21

Similar Documents

Publication Publication Date Title
ATE412006T1 (de) Anti-retrovirale immunogene, ihre darstellung und verwendung
DE69720389D1 (de) Zementzusammensetzungen und ihre Verwendung
DE69713379D1 (de) Zusammensetzungen auf basis von sphingomyelinase und ihre verwendung
DE50213336D1 (de) Substituierte 2-thio-3,5-dicyano-4-phenyl-6-aminopyridine und ihre verwendung
ATA188592A (de) Alkyl-bisacylphosphinoxide, diese enthaltende zusammensetzungen und ihre verwendung
DE60127997D1 (de) 1,5-benzothiazepine und ihre verwendung als antihyperlipidämika
DE50207849D1 (de) Substituierte 2-oxy-3,5-dicyano-4-aryl-6-aminopyridine und ihre verwendung
DE59712887D1 (de) Substituierte phenylketoenole und ihre verwendung als schädlingsbekämpfungsmittel
DE69637691D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
DE69638056D1 (de) Azeotropähnliche zusammensetzungen und ihre verwendung
DE60027479D1 (de) Harzstruktur und ihre verwendung
DE69529026T2 (de) Trehalose, ihre Herstellung und ihre Verwendung
DE69840599D1 (de) Antimikrobielle chinolone, ihre zusammensetzungen und ihre verwendungen
DE69820397D1 (de) Ätzmittel und ihre Verwendung
ATE448238T1 (de) 3-beta-d-ribofuranosylthiazolo(4,5- delta)pyridimin-nucleoside und ihre verwendung
ATE251892T1 (de) Schäumende öl-zusammensetzung und ihre verwendung
DE69525676D1 (de) Polyurethan-Zusammensetzungen, ihre Herstellung und Verwendung
DE59709806D1 (de) Cycloolefincopolymere, ihre verwendung und daraus hergestellte formkörper
DE60016326D1 (de) Wasser-absorbierende Zusammensetzung und ihre Verwendung
DE60027927D1 (de) Harzstruktur und ihre verwendung
DE69835433D1 (de) Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
DE69806419D1 (de) Harzzusammensetzung und ihre Verwendung
DE69620914D1 (de) Perfluoralkoxycycloalkancarbonylfluorid-zusammensetzungen und ihre verwendung
DE69810521D1 (de) Abbeizzusammensetzungen, ihre Herstellung und Verwendung
DE50008549D1 (de) Triazolotriazinone und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties